Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

RIGL vs SIGA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RIGL Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

RIGL Overall Winner 6-Pillar Tally: RIGL 4 – 2 SIGA Matrix Metrics: RIGL 8 – 2 SIGA

As of Nov 19, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RIGL carries a Unified Composite Score of 61.3/100 (BUY) at $41.19 (8.6x Forward P/E, 26.3% operating margin), whereas SIGA carries 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin).

  • Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.3); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RIGL vs SIGA
RIGL NASDAQ Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$41.19
-3.15% 1D
Market Cap $800.8M
TTM Revenue $288M
Forward P/E 8.6x
Beta / 30D Vol 1.06β · 72% Vol
Unified Composite Score
61.3 / 100 BUY
Tech 50.0 Fund 63.0 Flow 67.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.3 · SMA20: $46.46 · SMA50: $47.04
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.6%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $3.02 · SMA50: $3.14

6-Pillar Scorecard Institutional Category Breakdown (RIGL 4 – 2 SIGA)

Columns: Metric · RIGL · SIGA
1. Valuation Multiples SIGA
Forward P/E 8.6x 2.5x
Trailing P/E 2.6x N/M
PEG Ratio N/M 3.37x
EV / Revenue 2.6x 1.4x
2. Growth & Scale RIGL
Revenue Growth (YoY) +16.5% -49.7%
Earnings Growth (YoY) -55.5% -65.3%
TTM Revenue (USD) $288M $52M
Market Cap $800.8M $187.9M
3. Profitability & Quality RIGL
Gross Margin 70.7% 23.4%
Operating Margin 26.3% -14.2%
Net Profit Margin 106.6% 1.3%
Return on Equity (ROE) 109.2% 0.4%
4. Balance Sheet & Cash Flow RIGL
Cash Generation (TTM) $19M -$12M
Cash Flow Margin 6.7% -22.1%
Net Cash / Leverage $39M Net Cash $116M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIGA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 69.0% (5th %ile) 81.4% (8th %ile)
Put/Call OI Skew 0.03x (Call-Skewed) 0.04x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat RIGL
OpEx & R&D Intensity 44.4% of Rev ($128M) 37.6% of Rev ($20M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RIGL (8) vs SIGA (2)
Institutional Metric RIGL SIGA Criterion Row Edge
Market Capitalization
Scale
$800.8M $187.9M Larger Scale RIGL
Trailing P/E Ratio
Valuation
2.6x N/M Lower Multiple RIGL
Forward P/E Ratio
Valuation
8.6x 2.5x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
+16.5% -49.7% Higher Growth RIGL
Operating Margin (TTM)
Profitability
26.3% -14.2% Higher Margin RIGL
Net Profit Margin
Profitability
106.6% 1.3% Higher Margin RIGL
Return on Equity (ROE)
Capital Efficiency
109.2% 0.4% Higher ROE RIGL
52-Week Range Position
Momentum
59% ($25–$53) 3% ($3–$7) Stronger Trend RIGL
Beta / 30D Volatility
Risk Regime
1.06β · 72% Vol 0.75β · 65% Vol Lower Realized Risk SIGA
Unified Institutional Score
Composite Signal
61.3 / 100 (BUY) 47.5 / 100 (HOLD) Higher Composite RIGL
Trailing 12M Revenue (USD)
Operating Scale
$288M $52M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.7% 23.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev 3.37x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$19M ($39M Net Cash) -$12M ($116M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SIGA +0.67 pp
RIGL: -15.73% · SIGA: -15.06%
3M Horizon RIGL +2.59 pp
RIGL: -10.24% · SIGA: -12.83%
6M Horizon RIGL +84.85 pp
RIGL: +41.11% · SIGA: -43.74%
1Y Horizon RIGL +44.73 pp
RIGL: -10.88% · SIGA: -55.61%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RIGL Revenue SIGA Revenue RIGL Op. Margin SIGA Op. Margin Margin Leader
FY2018 $40M $480M -163.3% 74.4% SIGA
FY2019 $60M $30M -116.5% -8.7% SIGA
FY2020 $110M $120M -26.7% 67.6% SIGA
FY2021 $150M $130M -8.4% 66.7% SIGA
FY2022 $120M $110M -46.2% 38.5% SIGA
FY2023 $120M $140M -17.5% 59.8% SIGA
FY2024 $180M $140M 13.5% 50.4% SIGA
FY2025 $290M $90M 42.6% 25.1% RIGL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RIGL CONSOLIDATION
94d in phase · OBV NEUTRAL
Current IV 69.0%
IV Percentile 5th %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RIGL Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $800.8M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($128M)
90D Engineering Disclosures 0 Published
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published

Investor FAQ RIGL vs SIGA Key Questions & Quantitative Answers

As of Nov 19, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RIGL carries a Unified Composite Score of 61.3/100 (BUY) at $41.19 (8.6x Forward P/E, 26.3% operating margin), whereas SIGA carries 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin). Technical & Structure Timing Caution: RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.3); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RIGL leads the Growth & Scale pillar: RIGL posts +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin), compared with SIGA at -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RIGL cumulative revenue shifted +625.0% while SIGA shifted -81.2%. In operating R&D and SG&A reinvestment, RIGL deploys 44.4% of Rev ($128M) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($20M) (0 disclosures) for SIGA.

SIGA screens cheaper on headline valuation multiples. RIGL trades at 8.6x Forward P/E, 2.6x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (6.7% FCF margin), whereas SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RIGL (109.2% ROE) versus SIGA (0.4% ROE) capital efficiency.

In options market volatility and institutional positioning, RIGL carries 69.0% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 72% Vol realized risk). By comparison, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.